About

Gastrointestinal stromal tumors are the most common connective-tissue cancers of the digestive system, driven primarily by mutations in the KIT gene. Bezclastinib is a small-molecule pill designed to selectively block the specific mutated KIT protein that fuels these tumors. By precisely targeting this driver mutation, the drug could potentially control tumor growth in patients who have stopped responding to prior therapies.